By skyforbes 
Center for Medicare and Medicaid Services (CMS) has made the historic move to approve Foundation’s cancer gene test. [1] It’s a great milestone for the future of healthcare, but it also raises unresolved issues in the following three aspects.
1. Reimbursement Cycle
Reimbursement of genetic tests will increase in both public and commercial sectors soon. CMS has led the way. Private insurers will follow in CMS’s footstep. The more genetic tests approved by U.S. Food and Drug Administration (FDA), the more CMS will continue to approve those reimbursements. Personalized treatments will be possible for patients who need them. It is a win-win situation for everyone, right?
2. Shortage of Genetic Counselors
Do most physicians feel comfortable interpreting the results from genetic tests and create actionable treatments? It’ll be beneficial to have genetic counselors to guide both physicians and patients through the treatment process. However, there are not enough genetic counselors in the world to face the rising demand. [2]
3. A Comprehensive Test Being Used for A Limited Purpose
It’ll be possible to tell everything you need to know about a patient with one genetic…